Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 6/20 | 0.41 |
| ▸ | MMP13 | P45452 | 3/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | MMP9 | P14780 | 4/20 | 0.40 |
| ▸ | MMP12 | P39900 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12225877 | 0.84 | PSMB5 (0.46) | NPY5RRXFP1POLBMMP2MMP13 | |
| SCHEMBL16458816 | 0.76 | MMP2 (0.46) | NPY5RPOLBMMP2MMP13ADAMTS4 | |
| SCHEMBL16459579 | 0.76 | CTSL (0.43) | NPY5RPOLBMMP2ADAMTS4F2 | |
| SCHEMBL16458894 | 0.75 | MMP2 (0.47) | NPY5RMMP2MMP13ADAMTS4MMP9 | |
| SCHEMBL16458533 | 0.75 | MMP2 (0.51) | NPY5RPOLBMMP2MMP13ADAMTS4 | |
| SCHEMBL16457746 | 0.74 | MMP2 (0.44) | NPY5RPOLBMMP2MMP13ADAMTS4 | |
| SCHEMBL19347783 | 0.74 | ADAMTS4 (0.47) | NPY5RMMP2MMP13ADAMTS4F2 | |
| SCHEMBL16459707 | 0.74 | MMP2 (0.47) | NPY5RPOLBMMP2MMP13ADAMTS4 | |
| SCHEMBL16459055 | 0.74 | MMP2 (0.47) | NPY5RPOLBMMP2MMP13ADAMTS4 | |
| SCHEMBL27542487 | 0.74 | MMP13 (0.65) | POLBMMP2MMP13ADAMTS4MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140011998-A1 | DERIVATIVES OF 1-AMINO-2-CYCLOPROPYLETHYLBORONIC ACID | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011998-A1 | DERIVATIVES OF 1-AMINO-2-CYCLOPROPYLETHYLBORONIC ACID | PSMB6, PSMB5, PSMB1 | NPY5R 4010/4885RXFP1 4660/4885POLB 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.